The Potential of ZICURMA Herbal Supplement in Inhibiting Pro-Inflammatory Cytokines as Therapeutic Agents in SARS-CoV2 Infection
DOI:
https://doi.org/10.48048/tis.2023.4146Keywords:
COVID-19, Curcuma, Ginger, In silico, TurmericAbstract
nSARS-CoV2 causes pneumonia and acute respiratory distress syndrome that involves exacerbated pro-inflammatory cytokines hyperproduction. ZICURMA, zing-curcuma is a tonic developed from ginger, turmeric, and curcuma that may be adequate to remedy nSARS-CoV2 infections. Therefore, this study aims to predict the effectiveness and possible inhibition of potentially bioactive compounds in ZICURMA against pro-inflammatory cytokines through a molecular docking approach. Three bioactive compounds were identified and extracted from KnapSackFamily, namely bisacumol, curcumin and desmetoxycurcumin; then, the 3D structures were generated from PubChem. The protein targets were prepared using an open babel program integrated into PyRx 0.8; there were TN-α, IL-6 / IL-6R, and IL-1 / IL-1R, respectively. The results showed that the ligands had moderate to solid binding affinity with values ranging from –5.0 kcal/mol to –9.0 kcal/mol. However, it offers a mismatch of bonds, including between curcumin compounds and IL-6, IL-6R, IL-1R and IL-1ß. In silico simulation proves that the bioactive compound in ZICURMA does not allow binding to IL-6, IL-6R, IL-1R and IL-1ß proteins. However, it cannot be used as a standard reference to determine the feasibility of bisacumol, desmethoxycurcumin, and curcumin as an anti-viral candidate. Further in-vitro researches should be conducted to validate the potency of ZICURMA as an anti-viral infection.
HIGHLIGHTS
The main finding of this research includes:
- The ZIRCUMA or a tonic beverage produced using Zingiber officinale (ginger), Curcuma domestica (turmeric) and C. xanthorhiza (curcuma) contain three most identical bioactive compound, bisacumol, curcumin, and desmethoxycurcumin
- Bisacumol, curcumin, and desmethoxycurcumin potentially have a strong interact to inflammatory cytokine (that involved in COVID-19 infection) in in-silico simulation
- The binding interaction is dominated by conventional H-bonds that representing a strong type of interaction. However, the presence of unfavorable donor-donor and unfavorable acceptor-acceptor binding in several interaction should be noted as a possible incompatibility junction
- Even though it has a strong interaction in in-silico model, the main bioavailability mechanism of bisacumol, curcumin, and desmethoxycurcumin as immunomodulator related to the COVID-19 systemic inflammation in lung organ still unclear
GRAPHICAL ABSTRACT
Downloads
Metrics
References
Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), Johns Hopkins Coronavirus Resource. Cent. (2022), Available at: https://coronavirus.jhu.edu/map.html, accessed June 2022.
Kementerian Kesehatan Republik Indonesa. COVID-19 Situation Dashbord, Sub Direktorat Penyakit Infeksi Emerging, Ministry of Health of the Republic of the Indonesia (2022), Available at: https://covid19.go.id/peta-sebaran, accessed June 2022.
J Guarner. Three emerging coronaviruses in two decades. Am. J. Clin. Pathol. 2020; 153, 420-1.
H Liu, S Chen, M Liu, H Nie and H Lu. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: A systematic review and meta-analysis. Aging Dis. 2020; 11, 668-78.
D Ragab, HS Eldin, M Taeimah, R Khattab and R Salem. The COVID-19 cytokine storm; What we know so far. Front. Immunol. 2020; 11, 1446.
B Hu, S Huang and L Yin. The cytokine storm and COVID-19. J. Med. Virol. 2021; 93, 250-6.
X Sun, T Wang, D Cai, Z Hu, J Chen, H Liao, L Zhi, H Wei, Z Zhang, Y Qiu, J Wang and A Wang. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020; 53, 38-42.
DL Sykes, L Holdsworth, N Jawad, P Gunasekera, AH Morice and MG Crooks. Post-COVID-19 symptom burden: What is long-COVID and how should we manage it? Lung 2021; 199, 113-9.
AM Baig. Chronic COVID syndrome: Need for an appropriate medical terminology for long-COVID and COVID long-haulers. J. Med. Virol. 2021; 93, 2555-6.
S Felsenstein, JA Herbert, PS Mcnamara and CM Hedrich. COVID-19: Immunology and treatment options. Clin. Immunol. 2020; 215, 108448.
C Stasi, S Fallani, F Voller and C Silvestri. Treatment for COVID-19: An overview. Eur. J. Pharmacol. 2020; 889, 173644.
SA Bhat, SA Rather, A Iqbal, HA Qureshi and N Islam. Immunomodulators for curtailing COVID-19: A positive approach. J. Drug Deliv. Ther. 2020; 10, 286-94.
RV Nugraha, H Ridwansyah, M Ghozali, AF Khairani and N Atik. Traditional herbal medicine candidates as complementary treatments for COVID-19: A review of their mechanisms, pros and cons, evidence-based complement. Altern. Med. 2020; 2020, 2560645.
J Li, R Thangaiyan, K Govindasamy and J Wei. Anti-inflammatory and anti-apoptotic effect of zingiberene on isoproterenol-induced myocardial infarction in experimental animals. Hum. Exp. Toxicol. 2021; 40, 915-27.
MAEH Mousa, H Mansour, F Eid and A Mashaal. Anti-inflammatory activity of ginger modulates macrophage activation against the inflammatory pathway of monosodium glutamate. J. Food Biochem. 2021; 45, e13819.
J Dai, L Gu, Y Su, Q Wang, Y Zhao, X Chen, H Deng, W Li, G Wang and K Li. Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. Int. Immunopharmacol. 2018; 54, 177-87.
RHA Khudir, MA El-Ghannam, AF Salama, EM Tousson and SM El-Dsoki. Curcumin attenuated oxidative stress and inflammation on hepatitis induced of by fluvastatin in female albino rats. Alex. J. Vet. Sci. 2019; 62, 102-15.
NM O’Boyle, M Banck, CA James, C Morley, T Vandermeersch and GR Hutchison. Open Babel: An open chemical toolbox. J. Cheminform. 2011; 3, 33.
FLVD Veerdonk and MG Netea. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit. Care 2020; 24, 445.
VJ Costela-Ruiz, R Illescas-Montes, JM Puerta-Puerta, C Ruiz and L Melguizo-Rodríguez. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020; 54, 62-75.
O Trott and AJ Olson. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010; 31, 455-61.
J Eberhardt, D Santos-Martins, AF Tillack and S Forli. AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 2021; 61, 3891-8.
S Maiti, A Banerjee, A Nazmeen, M Kanwar and S Das. Active-site molecular docking of nigellidine with nucleocapsid-NSP2-MPro of COVID-19 and to human IL1R-IL6R and strong antioxidant role of Nigella-sativa in experimental rats. J. Drug Target. 2022; 30, 511-21.
K Zia, S Ashraf, A Jabeen, M Saeed, M Nur-e-Alam, S Ahmed, AJ Al-Rehaily and Z Ul-Haq. Identification of potential TNF-α inhibitors: From in silico to in vitro studies. Sci. Rep. 2020; 10, 20974.
NK Shinada, AGD Brevern and P Schmidtke. Halogens in protein-ligand binding mechanism: A structural perspective. J. Med. Chem. 2019; 62, 9341-56.
MR Bauer and MD Mackey. Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein-ligand complexes. J. Med. Chem. 2019; 62, 3036-50.
JO Njoku, DA Silva, D Mukherjee, GK Webster and R Löbenberg. In silico tools at early stage of pharmaceutical development: Data needs and software capabilities. AAPS PharmSciTech 2019; 20, 243.
S Ahmad, Y Waheed, A Abro, SW Abbasi and S Ismail. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. J. Mol. Model. 2021; 27, 206.
N Sawyer, AM Watkins and PS Arora. Protein domain mimics as modulators of protein-protein interactions. Acc. Chem. Res. 2017; 50, 1313-22.
SN Dishman, CJ Laconsay, JC Fettinger, DJ Tantillo and JT Shaw. Divergent stereochemical outcomes in the insertion of donor/donor carbenes into the C-H bonds of stereogenic centers. 2022; 13, 1030-6.
M Arba, Yamin, S Ihsan and DH Tjahjono. Computational approach toward targeting the interaction of porphyrin derivatives with Bcl-2. J. Appl. Pharm. Sci. 2018; 8, 60-6.
S Sharma, I Ali and B Bezbaruah. Quantum mechanical study on the effect of pi-pi stacking interactions on phenolic systems and their compatibility with some polar solvents. J. Chem. Chem. Sci. 2017; 7, 1311-30.
S Scheiner, M Michalczyk and W Zierkiewicz. Coordination of anions by noncovalently bonded σ-hole ligands. Coord. Chem. Rev. 2020; 405, 213136.
Y Zhou, M Xie, Y Song, W Wang, H Zhao, Y Tian, Y Wang, S Bai, Y Zhao, X Chen and G She. Two traditional chinese medicines curcumae radix and curcumae rhizoma: An ethnopharmacology, phytochemistry, and pharmacology review. Evid. Based Complement. Altern. Med. 2016; 2016, 4973128.
Y Manoharan, V Haridas, KC Vasanthakumar, S Muthu, FF Thavoorullah and P Shetty. Curcumin: A wonder drug as a preventive measure for COVID19 management. Indian J. Clin. Biochem. 2020; 35, 373-5.
D Mathew and WL Hsu. Antiviral potential of curcumin. J. Funct. Foods 2018; 40, 692-9.
FDS Quemel, AP Dantas, L Sanches, ACGA Viana, ES Silva, ER Monteiro, ZC Gazim, JE Gonçalves and AD Lopes. Chemotypes of turmeric (Curcuma longa L.) essential oil from four different states of Brazil. Aust. J. Crop Sci. 2021; 15, 1035-42.
Z Liu and Y Ying. The inhibitory effect of curcumin on virus-induced cytokine storm and its potential use in the associated severe pneumonia. Front. Cell Dev. Biol. 2020; 8, 479.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
